ReviewFrontiers in pharmacology2025
Role of transient receptor potential (TRP) channels in osteoarthritis: a comprehensive review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune heterogeneity-driven therapeutic responses to platelet-rich plasma and TRPV1 antagonism in osteoarthritis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a chronic degenerative joint disease, primarily characterized by the degeneration of articular cartilage, synovial inflammation, and persistent pain, which severely impairs the quality of life for hundreds of millions of patients worldwide. Transient receptor potential (TRP) channels, a group of non-selective cation channels activated by various physicochemical stimuli, play a crucial role in the pathogenesis of OA. This review systematically explores the roles of the different TRP channel subfamilies, including TRPV, TRPA, TRPC, and TRPM, in OA-affected joint tissues. It highlights how TRP channels contribute to cartilage degradation and synovitis through multiple mechanisms, including the modulation of intracellular calcium signaling, the regulation of inflammatory responses, and the control of chondrocyte metabolism, apoptosis, and ferroptosis. Additionally, the critical role of TRP channels as molecular sensors of pain is discussed in detail. These channels have been shown to both mediate the initiation and transmission of nociceptive signals in sensory neurons, and to enhance pain sensitivity through interactions with immune cells. Consequently, targeting TRP channels with specific agonists or antagonists has emerged as a promising strategy for developing novel analgesics. This review outlines recent clinical progress and the therapeutic promise of targeting the TRP channel network for OA pain relief and disease modification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.